Group 2 innate lymphoid cells (ILC2) are innate immune cells that respond rapidly to their environment through soluble inflammatory mediators and cell-to-cell interactions. As tissue-resident sentinels, ILC2 help orchestrate localized type 2 immune responses. These ILC2-driven type 2 responses are now recognized in diverse immune processes, different anatomical locations, and homeostatic or pathological settings. ILC2-derived cytokines and cell surface signaling molecules function as key regulators of innate and adaptive immunity. Conversely, ILC2 are governed by their environment. As such, ILC2 form an important nexus of the immune system and may present an attractive target for immune modulation in disease.
Introduction
In 2010, murine group 2 innate lymphoid cells (ILC2) were formally described as a novel ILC population that promoted type 2 immunity. [1] [2] [3] ILC2 are tissue-resident immune cells important for orchestrating local type 2 inflammation, found to be enriched at mucosal and barrier surfaces. 4 Functionally, ILC2 are mainly described for their role in promoting protective immunity to helminth infections, tissue repair, metabolic homeostasis, and allergic inflammation. [5] [6] [7] ILC2 belong to a larger family of ILC that parallel the adaptive immune system in function but lack antigen specificity (for a review of ILC lineages, see Ref. 8) .
ILC distinctively lack antigen-specific receptors and are activated in an antigen-independent manner. This enables ILC to rapidly respond to changes in their microenvironment without the need for adaptive immune cell priming. 9 More specifically, ILC express germline-encoded inhibitory or activating receptors that regulate their activity and enable prompt modulation of function. This central feature of innate immunity has put forth the hypothesis that ILC can instruct the direction of downstream innate and adaptive immune responses by providing early polarizing cues. Indeed, natural killer (NK) cells, in addition to their natural cytotoxic function, are critical regulators of innate and adaptive immune functions. NK cells possess rudimentary features of immune memory and can help influence the development of type 1 adaptive immunity, but also limit inflammation. 10, 11 Similarly, group 3 ILC (ILC3) are known to drive downstream innate and adaptive immune responses. 12 Thus, it is clear that several ILC lineages have important immuneregulatory functions.
ILC2 were formally discovered in gut-associated tissues of mice, [1] [2] [3] although their presence was previously hypothesized based on the observation that T and B cell-deficient (recombinationactivating gene, Rag1 -/-and Rag2 -/-) mice were able to mount type 2 responses. [13] [14] [15] ILC2 were subsequently discovered at other barrier sites, such as the airways and skin, where they participated in type 2 inflammation. In contrast to T and B cells of the adaptive immune system, ILC2 are sparse in secondary lymphoid organs but enriched at mucosal and barrier sites. Moreover, ILC2 are also present in numerous other tissues under homeostatic conditions. Parabiosis experiments have shown ILC2 to be tissue-resident cells that are doi: 10.1111/nyas.13604 maintained and expanded locally under physiological and pathological conditions. 16, 17 The physical location of ILC2 suggests that they may be important in regulating local immune responses. In this review, we first summarize ILC2 development and identification (see Ref. 18 for a comprehensive review), followed by a review of their regulation and effector function in different anatomical sites during homeostasis and disease.
ILC2 development and identification
ILC2 derive from bone marrow hematopoietic stem cells in a differentiation pathway from common lymphoid precursors or lymphoid primed multipotent precursors. These early precursors are known to require ID2, as well as transient NFIL3 expression, 19 for their development and give rise to early innate lymphocyte precursors (EILPs), which can differentiate into all ILC subtypes, including NK cells. 18, 20 Downstream of multipotent EILP are more lineagerestricted progenitors such as the common innate helper innate lymphoid precursors that further develop into ILC2 lineage-restricted progenitors, under the transcriptional control of Id2, Zbtb16, Tcf7, Tox, and Bcl11b. 18, [20] [21] [22] [23] Current data are consistent with a model in which multipotent progenitor cells give rise to unipotent ILC precursors that have a more specific cell fate 18 ( Fig. 1) . Recently, it was observed that a loss of the transcription factor (TF) promyelocytic leukemia zinc finger protein (PLZF) (encoded by Zbtb16) has long-term effects on the functional properties of mature ILC2. 24 So far, the origin of human ILC2 is unclear; however, it was shown that all human ILC subpopulations in secondary lymphoid tissues could be derived from a ROR␥ t + progenitor. 25 As described above and depicted in Figure 1 , proper development and function of ILC2 are dependent on several TFs, including those expressed by Gata3, 26, 27 Rora, 28, 29 Gfi1, 30 Tcf7, 31, 32 Ets1, 33 and Bcl11b. 34 However, these TFs are also expressed by other lymphoid lineages, which rely on some for their function or differentiation. How exactly these different TFs regulate ILC2 differentiation is incompletely understood, although individual TFs can promote ILC2 reactivity to certain alarmins (e.g., IL-25 and IL-33) by upregulating their receptor expression and stimulating type 2 cytokine (IL-4, IL-5, and IL-13) production.
35 GATA3 in particular is recognized as a master regulator of type 2 effector genes, cell proliferation, and lineage stability. 35 Importantly, while critical for ILC2 development and function, GATA3 also has upstream functions in ILC and T cell development. [35] [36] [37] While less is known about the regulation of GATA3 in ILC2, its expression in T helper 2 (T H 2) cells is known to depend on IL-4-mediated STAT6 signaling, as well as TCRand/or IL-2-dependent pathways. 35 Moreover, Gata3, in addition to Tcf7 and Bcl11b, has been shown to be a Notch-dependent target, which might explain the strong impact of Notch signals on promoting ILC2 development and differentiation in vitro. 28, 31, 38 Phenotypically, mouse and human ILC2 can be identified by the absence of surface markers expressed by other hematopoietic lineages ("lineage-negative") but with positive staining for CD45 and CD127 (IL-7R␣). Without a known ILC2-specific marker, additional identifying features must be incorporated for their reliable detection by flow cytometry or immunofluorescence microscopy. For mice, these markers may include surface signaling receptors, such as ICOS, KLRG1, CD25, CD117, ST2 (Il1rl1, IL-33 receptor component), and IL-17RB (IL-25 receptor component), or intracellular targets associated with ILC2 function, such as GATA3, IL-5, or IL-13. In mice, gene-reporter animals provide an additional invaluable means to identify ILC2. In humans, ILC2-associated markers include CD117, CD161, and CRTH2, 39, 40 the latter being the receptor for prostaglandin D 2 (PGD 2 ), as well as GATA3 (see Ref. 41 for a more exhaustive list).
In terms of epigenetic regulation, ILC2 effector genes are in a constitutive open chromatin conformation that, like their adaptive CD4
+ T H 2 counterparts, is distinct from other ILC or T helper cell lineages. 9 It has recently been shown that the lysine methyltransferase G9a promotes expression of ILC2 genes, implicating epigenetic regulation in their lineage commitment. 42 Similarly, posttranscriptional regulation by microRNA (miRNA)-155 was shown to be important for proper ILC2 function in a model of allergic airway inflammation. 43 More recently, it was described that miR-17ß92 has important implications for ILC2 homeostasis, and, additionally, miR-17ß92-deficient ILC2 were shown to be defective in cytokine expression upon IL-33-or thymic stromal lymphopoietin (TSLP)-induced allergic airway inflammation. Moreover, the miR-17ß92 cluster member miR-19a was found to specifically promote IL-5 and IL-13 production, by inhibiting the expression of signaling inhibitors, including SOCS1 and A20. 44 Nevertheless, no TF or other gene is known to be exclusively expressed by ILC2, thus complicating genetic targeting strategies.
Regulation of ILC2 activation
As mentioned above, tissue-resident ILC2 do not express antigen-specific receptors and are regulated by germline-encoded receptors. As such, ILC2 are positioned to integrate local cues from the epithelium, microbiota, other immune cells, and pathogens in their environment to modulate inflammation. Nonhematopoietic cell-derived type 2 alarmins, including IL-25, IL-33, and TSLP, are essential for the activation of ILC2. 2, 45, 46 These alarmins, together with other coregulatory molecules, govern the function of ILC2 (Fig. 2) . 48 IL-25 plays a more prominent role in activating gut-associated ILC2, 49, 50 where it is particularly produced by epithelial tuft cells. Although the specific stimuli that prompt IL-25 release from tuft cells are unclear, it is known that IL-25-driven activation of ILC2 plays a central role in anti-helminth parasite immune responses. Interestingly, steadystate ILC2 in the gut produce IL-13, enhancing the epithelial-stem cell compartment to promote a basal level of tuft cell development. In turn, tuft cells produce IL-25, maintaining ILC2 activation in the steady-state gut. 51, 52 During primary helminthic infection, such as with Nippostrongylus brasiliensis, or after exposure to the key fungal component chitin, the ILC2-tuft cell axis is enhanced by tuft cell chemosensory signaling molecule TRPM5 and IL-13 produced by ILC2. 53, 54 In this model, IL-13 enhances tuft cell differentiation from epithelial precursors in the intestine, indicating a positive feedback mechanism between ILC2 and the gut epithelium. This further stimulates intestinal goblet cell hyperplasia and mucous secretion that is important for parasite expulsion. 55, 56 These data provide clear evidence of the importance of IL-25-activated ILC2 primary helminth infection and worm expulsion in the gut.
IL-25

IL-33
IL-33 is a member of the IL-1 cytokine family that, unlike IL-1␤ and IL-18, does not require processing by caspases to be biologically active. 57 IL-33 is sequestered in the nucleus and can be released in a passive manner during necrotic cell death, functioning as an alarmin. However, under conditions of apoptotic cell death, IL-33 is rendered inactive by proteolytic cleavage by caspase-1 and/or caspases-3 and -7. 58 In nonexacerbated asthmatics, IL-33 is expressed with deletion of Il33 exons 3 and 4 ( exon 3,4), conferring IL-33 cytosolic localization and facilitating its secretion. This splicing variant form of IL-33 mRNA is strongly associated with type 2 immunity, whereas full-length IL-33 is not. 59 Moreover, the activity of full-length IL-33 protein can be further increased through alternative proteolytic cleavage after secretion into the extracellular milieu. 60 Although Il33 is constitutively expressed in the nucleus of many cell types, expression can be further increased during inflammation. Upregulation of IL-33 protein has been observed in alveolar type II epithelial cells upon exposure to ovalbumin, chitin, or Alternaria alternata. [61] [62] [63] IL-33 is known to activate ST2 + ILC2, and thus initiating an innate type 2 inflammatory response, through the production of IL-5 and IL-13. In the lung, several allergens, e.g., house dust mite (HDM), A. alternata, and papain, have also been reported to stimulate lung ILC2 via the release of IL-33. [64] [65] [66] IL-33 stimulation induces NF-B p65, JNK, and p38 MAPK; the latter subsequently induces the phosphorylation of GATA3 in ILC2. Phosphorylation of GATA3 by p38 strongly increases GATA3 binding to the Il5 and Il13 promoters, but not the promoter of Il6, and, interestingly, p38 MAPK inhibition during the early phase of stimulation significantly suppressed IL-33-induced production of IL-5 and IL-13. 67 Recent work in mice has revealed that in the very early postnatal stages, type 2 immunity is mediated by elevated IL-33 expression in the lung, which is dependent on ILC2 but not CD4 + T cells. 68 In adult mice, IL-33 and T cell-derived IL-2 expanded ILC2 populations in the lung in a model of Nippostrongylus brasiliensis infection that led to larval damage. 69 The release of IL-1␤ primes ILC2 to further increase their responsiveness to IL-33 and IL-25. 70, 71 Recently, ATP-activated mast cells in the gut were found to increase ILC2 activation in part through increased IL-33 production. 72 In an indirect mechanism, IL-33-activated mast cells in the lung may activate ILC2 through production of lipid mediators, like leukotriene D4 (LTD 4 ) and PGD2, as discussed in more detail below.
73
ILC2 engagement by IL-33 induces the activation of the ERK signaling pathway, which is negatively regulated by Sprouty-related Ena/VASP homology 1 domain-containing protein 1 (SPRED1). SPRED1 suppresses both secretion of type 2 cytokines and proliferation apoptosis of ILC2 via the stabilization of GATA3. As SPRED1 is highly expressed in IL-33-activated lung ILC2, SPRED1 may be involved in a negative feedback loop affecting the IL-33-activated ERK signaling pathway. 74 Induction of IL-33 and TSLP by lung epithelial cells after chitin exposure or helminthic infection has further been reported to induce an interferon regulatory factor 4 (IRF4)-IL-9 program in ILC2, which promotes rapid IL-5 and IL-13 production required for optimal epithelial responses. 75 Moreover, constitutive expression of IL-9 by ILC2 after IL-33 (and TSLP) exposure can act in an autocrine manner to prolong survival of ILC2 in the tissue and prevent apoptosis of these cells, thereby enhancing ILC2-induced type 2 immune responses. 76, 77 In general, IL-33 is recognized as the main cytokine activating ILC2; however, it becomes increasingly clear that there are many other soluble and nonsoluble factors implicated in ILC2 activation.
TSLP
TSLP is suggested to be expressed mostly by epithelial cells and keratinocytes in the skin, gut, and lungs, although dendritic cells (DCs), mast cells, and basophils may also provide a cellular source for this cytokine. 78 A recent study revealed a subpopulation of tuft cells as another potential source of TSLP in the small intestinal epithelium. 79 TSLP is linked to multiple type 2-related diseases, such as atopic dermatitis (AD), asthma, and allergic responses. TSLP is an IL-7-like cytokine that binds the TSLP receptor, which forms a heterodimer with IL-7R␣, and is expressed on ILC2, T H 2 cells, DCs, and mast cells. 80 In contrast to the ILC2 populations in the lung and gut, which are critically dependent on IL-25 and IL-33 for their activation, skin and skin-draining lymph node ILC2 were found to be independent of these canonical cytokines, but instead were activated primarily by TSLP. 81 Recent studies have suggested that TSLP can contribute to ILC2 activation, promoting corticosteroid resistance in the context of IL-33-induced allergic airway inflammation. 82, 83 In humans, TSLP-stimulated ILC2 were shown to upregulate GATA3 and produce type 2 cytokines IL-4, IL-5, and IL-13. 27 Moreover, treatment of mild allergic asthmatics with an anti-TSLP monoclonal antibody (AMG 157) resulted in a significant reduction of allergen-induced airway eosinophils and bronchoconstriction. 84 These results indicate that TSLP serves an important role for ILC2 activation; however, it remains uncertain whether TSLP is a master switch in ILC2 activation or part of a concerted action by several parallel pathways.
Other cytokines that regulate ILC2
Apart from the canonical ILC2-activating cytokines IL-25, IL-33, and TSLP, other cytokines are also capable of inducing ILC2 responses, such as IL-2, IL-4, IL-7, and IL-9. IL-2 is known to be important for ILC2 survival and serves as a major cofactor in regulating ILC2 function during type 2 immunopathology in the lung. Indeed, while IL-2 alone was found to be insufficient to increase in vivo IL-13 production by ILC2, synergy between IL-2 and IL-33 augmented Il13 expression by ILC2. 85 Nevertheless, in vivo IL-2/anti-IL2 mAb treatment is commonly used to expand ILC2 in mice. It is likely that T cell-derived IL-2 synergizes with type 2 alarmins to promote ILC2 activation. 86 Similarly, IL-7 can synergize with IL-33 to promote ILC2 activation in vitro. 27, 64 Moreover, mice defective in IL-7 signaling are ILC2 deficient, indicating the importance of this cytokine for ILC2 development and/or homeostasis.
1,87,88 IL-9 also has a costimulatory function on ILC2, enhancing their survival. 77 Finally, basophil-or eosinophil-derived IL-4 is known to influence ILC2 by enforcing ILC2 lineage stability, proliferation, and function. 70, 89 Importantly, these cytokines require the common gamma (c ␥ ) chain as part of their receptors, and c ␥ chain-deficient mice or humans 90 lack ILC2. Moreover, ILC2 function can also be negatively influenced by both type I and type II interferon, as well as IL-27 signaling. 17, 70, [91] [92] [93] Suppression of ILC2 function by these cytokines has been shown to rely on the TF STAT1. 17, 94 Finally, ILC2 lineage plasticity and trans differentiation can be induced by IL-1␤, IL-12, and IL-18. 70, 71, 95, 96 Receptor-ligand interactions In addition to the soluble factors that regulate ILC2, a number of receptor-ligand interactions have been shown to mediate ILC2 activation. Tumor necrosis factor member TL1A (Tnfsf15) is expressed by endothelial and myeloid cells and binds DR3 expressed by T cells and ILC2. TL1A-DR3 interaction leads to ILC2 proliferation and expression of IL-5 in vivo and in vitro. 97, 98 The presence of IL-7 was shown to enhance this response, but to an extent well below that induced by IL-33. Like the mouse system, TL1A is less potent in humans than IL-33 and IL-25 but acts synergistically with both factors to drive an optimal ILC2 response. Human ILC2 have further been observed to express NKp30, which, upon interaction with its cognate-activating ligand B7-H6, induces the rapid production of type 2 cytokines. Interestingly, higher levels of B7-H6 expression were observed in lesions of AD patients. 99 In the lungs of allergic mice, ILC2 were found to express ICOS (as well as ICOS ligand), and interaction of ICOS with ICOS-L was observed to promote cytokine production, proliferation, and survival of ILC2 through STAT5 signaling. 100, 101 In contrast, KLRG1 expression and its binding to E-cadherin have been shown to inhibit human ILC2 function. 102 
Lipid mediators
Although generally involved in metabolism, bioactive lipids can influence key physiological mechanisms and cell signaling in mice and humans. 103 The first lipid mediator described to regulate ILC2 function was LTD 4 , which has very high affinity for cysteinyl leukotrienes receptor 1 (CysLT1R). As ILC2 endogenously express this receptor, LTD 4 induction, by A. alternata challenge, was shown to promote accumulation and enhance proliferation or ILC2, and drive robust production of IL-4 and IL-5 by ILC2. 104 Similarly, leukotriene C 4 given in combination with IL-33 has been shown to directly potentiate IL-5 and IL-13 production by ILC2, via activation of CysLT1R. 105 Interestingly, human ILC2 also express the proresolving receptor ALX/FRP2, which binds the resolvin lipoxin A 4 . Lipoxin A 4 has anti-inflammatory properties and inhibits IL-13 production by human peripheral blood-derived ILC2 when cocultured in the presence of IL-2, IL-25, IL-33, and PGD 2 .
106
The eicosanoid PGD 2 is the key prostaglandindriving type 2 inflammation, and its receptor (CRTH2) is selectively expressed on T H 2 cells and human ILC2. PGD 2 -CRTH2 signaling was shown to induce ILC2 migration, IL-4 production, and potentiate IL-25-and IL-33-mediated responses. 107 In mice, PGD 2 was also shown to drive ILC2 function and accumulation in the airways. 73 Notably, the inhibitory prostaglandin I 2 (PGI 2 ), or prostacyclin, has been suggested to attenuate allergic inflammation when ligated to its receptor (IP). 108 PGI 2 has been shown to inhibit human and mouse ILC2 responses, as IP ligation blocked ILC2 proliferation and induced apoptosis. Furthermore, IP-deficient mice displayed higher IL-5-and IL-13-expressing ILC2 in the lung after A. alternata challenge. 109 Recently, a study by Von Moltke and colleagues reported that, although largely dispensable for homeostasis, leukotrienes, especially LTB 4 and cysteinyl leukotrienes, play a nonredundant role in activating ILC2 in a manner that was shown to be dependent on nuclear factor of activated T cells (NFAT) signaling and worked in synergy with IL-33. 110 Interestingly, mucosal neuron-derived neuromedin U (NMU) also results in the activation of ILC2 and immediate production of type 2 cytokines downstream of the NFAT signaling cascade, 111 showing the wider importance of NFAT signaling in ILC2 activation.
Hormones
Transcriptional profiling of ILC has revealed that the androgen receptor (AR) is a prototypical ILC2 signature gene in tissue-resident ILC2. 112 This may suggest a role for hormones in the regulation of ILC2 function. Recent data have revealed that the development of ILC2 is greatly influenced by expression of the AR on progenitor ILC2. Engagement of the AR by its ligand, the male hormone androgen, inhibits differentiation of ILC2 progenitors into mature ILC2. 113 These data demonstrate that androgen signaling can regulate ILC2 development; however, as very few ILC2 develop from progenitors in adult mice, 16 it may well be that AR signaling imprints on steady-state numbers of ILC2.
Other hormones, like estrogen, have also been linked to airway hyperreactivity, although only in steady-state, as no differences were observed between wild-type and ER␣ gene knockout mice after allergen challenge. 114 However, this study does not specifically target ILC2. In all, very little is known about the hormonal control of ILC2.
Neuronal regulation
Neuronal control of ILC2 activation presents another dimension of immune regulation. Recently, it was found that the neurotransmitter adenosine, an ATP catabolite binding the adenosine receptor, can negatively regulate type 2 cytokine production by ILC2. 115 Others have described that ILC2 selectively express neuromedin U receptor 1 (NMUR1), and ILC2 in the mouse gastrointestinal tract, as well as the lung, colocalize with cholinergic neurons that express the neuropeptide NMU. 111, 116 Similarly, neurons were shown to interact with ILC3 and regulate their cytokine expression. 117 Interestingly, single-cell RNA sequencing data from IL-25-and IL-33-stimulated lung ILC2 revealed the NMUR1 was preferentially expressed during steady state and after IL-25 stimulation. 118 It was shown that NMU controls ILC2 downstream of the activation of calcineurin and NFAT. 111 In vitro, as well as in vivo, stimulation of ILC2 with NMU induced rapid cell activation, proliferation, and secretion of type 2 cytokines, resulting in accelerated clearance of the nematode N. brasiliensis. 111, 116 Additionally, the circadian synchronizer vasoactive intestinal peptide (VIP) activates ILC2 by binding its receptor VPAC, stimulating IL-5 release, and linking eosinophilic inflammation with metabolic cycling. 87 These studies very elegantly present evidence of a selective mechanism by which enteric neurons can provide neuroimmune cross talk and promote rapid type 2 immune responses at mucosal barriers.
Effector molecules produced by ILC2
As tissue-resident innate immune cells, ILC2 are positioned to rapidly respond to stimuli. Upon activation, ILC2 can express various soluble or membrane-bound effector molecules. These include the well-established IL-4, IL-5, IL-9, IL-13, and amphiregulin (Fig. 2) , but also other inflammatory molecules, such as IL-6, IL-8, IP10, and methionine-enkephalin (MetEnk). 27, 119 Moreover, ILC2 express surface-bound molecules, such as MHC class II, CD80/86, ICOSL, and OX40L, that may participate in immune-regulatory functions.
Cytokines
Initial identification of ILC2 was made possible by their expression of type 2 effector cytokines. [1] [2] [3] While Il4-EGFP reporter activity marks naive ILC2, protein expression is observed only in activated ILC2. 3, 104 Nevertheless, ILC2-derived IL-4 plays a role in polarizing T H 2 cells during helminth infection 120 and may also block the generation of allergen-specific T reg cells, thereby promoting food allergy. 121 In comparison to relatively scant production of IL-4, ILC2 are a potent cellular source of IL-13. Rapid secretion of IL-13 by ILC2 influences both immune and nonimmune cells. Myeloid cells, including macrophages and DCs, are activated by IL-13 to become polarized to an M2 or type 2 chemokine-secreting phenotype, respectively. ILC2-derived IL-13 also activates endothelial and epithelial cell types to express adhesion molecules or enhance the secretion of mucous from goblet cells. Importantly, IL-4 and IL-13 share common signaling components, and the overlapping roles of ILC2-derived IL-4 and IL- 13 are not yet understood (for more details, see review on IL-4/13 by Wynn 122 ). ILC2 are the main innate source of IL-5, a growth factor essential for eosinophil homeostasis. 87 The transcript for Il5 is constitutively expressed by a significant proportion of ILC2 in many anatomical locations, making the Il5-tdTomato reporter mouse an attractive model for ILC2 identification.
Although ILC2 can respond to IL-9, they are also an important source of this cytokine, leading to an autocrine signaling mechanism, as depicted in Figure 2 , that enforces IL-5 and IL-13 production. 76 While this feed-forward axis is essential for lung inflammation, IL-9-producing ILC2 were found to resolve inflammation in a model of allergen-induced arthritis through the activation of T reg cells. 123 This implies that IL-9 + ILC2 can yield different outcomes depending on their location and the inflammatory microenvironment. Although very little is known about the ILC2-T reg cell interaction, ILC2-T reg cross talk has been observed in studies focusing on helminth expulsion. 124 Furthermore, within the visceral adipose tissue and lung tissues, ILC2 and T reg cells were shown to localize to similar areas under homeostatic conditions, as well as in multiple other tissues after IL-33 stimulation. 91 Interestingly, after IL-33 administration or N. brasiliensis infection, ICOS-L + ILC2 and ICOS + T reg cells were found to accumulate in tissues, whereas T reg expansion in ICOS-L-deficient mice, or after treatment with ICOS-L monoclonal antibodies, was impaired, 91 suggesting that ICOS-L expression by ILC2 could promote T reg cell accumulation, thus providing a mechanism for ILC2 to communicate with T reg cells. Interestingly, a novel gut-resident ILC subset that secretes IL-10 has recently been described, 125 while another recent study identified IL-10 production in alternatively activated ILC2.
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ILC2 act mainly through secreting soluble mediators. Given the fact that ILC2 are tissueresident cells, their release of effector molecules in the microenvironment might be just the desired response for efficient signal transduction and amplification within the tissue. Apart from the classical type 2 cytokines, other ILC2 effector molecules have been described. For example, ILC2 are a main cellular source of amphiregulin, which is important for postinfection wound repair and for restoring epithelial integrity and lung function. 127 Additionally, MetEnk has been suggested to be an ILC2 effector of metabolic homeostasis by eliciting beiging of white adipose tissue after IL-33 stimulation. 119 Finally, ILC2 are also able to produce IL-2, 85 which, as with IL-9, may function in an autocrine or paracrine fashion.
In all, the effector molecules produced by ILC2 overlap to some degree with those produced by T cells; however, the unique functions of ILC2-secreted molecules need to be further defined using specific ILC2 depletion strategies.
Immune-regulatory cell surface molecules
In addition to soluble mediators, ILC2 can interact with other cells via surface-bound molecules. ICOS and KLRG1 are among the few molecules that can interact with surface-bound ligands. KLRG1 has, in the context of AD, been shown to act as an inhibitory receptor on ILC2, reducing ICL2 proliferation and expression of GATA3, as well as reducing IL5 and IL13 transcription, upon E-cadherin ligation. 102 Again, both ICOS and ICOS-L are coexpressed on ILC2, and cognate interaction between ICOS-L on ILC2 and ICOS on T cells after IL-33 stimulation has been proposed to mediate T reg cell accumulation. 91 Additionally, ICOS/ICOS-L interaction on ILC2 influences STAT5 signaling, promoting ILC2 proliferation and function in a model of allergic airway inflammation. 100 IL-33 has further been shown to upregulate OX40 ligand (OX40L) expression on ILC2, which was suggested to promote adaptive immunity via costimulation of T cells. 128 Additionally, OX40-OX40L ligation has been shown to enhance T H 2 cell number and survival. 129, 130 Regarding other surface molecules, namely, programmed death 1 (PD-1) receptor, its ligand PD-L1, and MHCII, PD-1 was recently shown to be upregulated on activated ILC2, and depletion of these PD-1 + ILC2 reduced papain-induced lung inflammation.
131 ILC2 can also express PD-L1, which has been proposed to promote CD4
+ T H 2 cell responses. 132 The expression of MHCII, CD80, and CD86 by mouse ILC2 has been shown to be involved in ILC2 interactions with CD4 + T cells; MHCII + ILC2 can induce T H 2 cell differentiation in vitro from naive CD4 + T cells, while MHCII-deficient ILC2 enhance T H 2 cell-driven helminth expulsion in vivo. 86, 128 
ILC2 immune function
Adipose tissue ILC2 are enriched in adipose tissue, where they were initially identified in murine white adipose tissue (WAT)-associated lymphoid clusters. 1, 133 WAT-associated ILC2 can regulate responses of eosinophils and alternatively activated macrophages (AAMs). 134 AAMs produce norepinephrine in response to eosinophil-derived IL-4, which leads to a beneficial caloric balance and beiging of WAT. 135 More recently, Artis and colleagues showed that IL-33 administration resulted in elevated numbers of ILC2 in WAT, which was associated with an increase in beige adipocytes, improved glucose tolerance, and increased weight loss. 119 Concurrently, it was shown that ILC2 and beige adipocyte numbers are reduced in WAT of Il33 -/-animals, while reconstitution of alymphoid mice with ILC2 was sufficient to promote WAT beiging, independent of the adaptive immune system, eosinophils, or IL-4 receptor signaling. However, recently, others have demonstrated that AAMs do not synthesize relevant amounts of norepinephrine in response to IL-4 and subsequently failed to induce the expression of thermogenic genes, like Ucp1, in adipocytes. 136 Therefore, the role of AAMs in adipocyte metabolism or adaptive thermogenesis is still subjected to some controversy. ILC2 were further reported to produce MetEnk peptides, leading to the upregulation of Ucp1 by adipocytes (in vitro) and promoting beiging in vivo. 119 MetEnk-treated animals upregulated the beige adipocyte marker Ucp1 in an IL-4-and IL-13-independent manner, as expression of neither cytokine changed upon MetEnk administration. 119 However, using tissuespecific deletion of the IL-4R␣ gene (Il4ra), Chawla and colleagues showed that IL-4 could act directly on PDGFR␣ + adipocyte progenitors to regulate genes associated with beige adipocyte differentiation, such as Ucp1, Klhl13, Tnfrsf9, and Tmem26, bypassing the AAM/norepinephrine axis. 137, 138 They also found that ILC2-derived IL-13, in synergy with eosinophilderived IL-4, might directly act on adipocytes through IL-4R␣ signaling to promote beige adipocyte development. 137 These studies suggest that ILC2 can interact with various cell types within adipose tissue to support metabolic homeostasis.
Interestingly, there is also evidence that the neuropeptide VIP, which is regulated by caloric intake, increases IL-5 production by ILC2, enhancing eosinophil responses associated with a lean state in mice. 87 Additionally, the ability of ILC2 to sense vitamin A deficiency suggests that ILC2 can respond to dietary factors in maintaining metabolic homeostasis. 139 In all, the above studies offer important insights in the role of ILC2 in homeostasis, as well as their potential to be involved in metabolic disease.
Airways
Type 2 immune responses are typically seen as the hallmark of allergic airway inflammation. 140 Genome-wide association studies (GWAS) of asthmatic patients have identified many ILC2-associated genes, such as RORA, IL33, IL1RL1, and IL13. 141 While ILC2 are the most prevalent ILC in the lungs of naive mice, they remain a relatively rare population among immune cells. 127 The emerging role of ILC2 in the development of allergic airway inflammation has been studied in various mouse models, using extracts of HDM 64, 142 (more recently in combination with polutants 143 ), protease-containing allergens (papain 64 and A. alternata 49 ), ovalbumin, 144 or chitin. 75 Early studies have linked ILC2 to the pathogenesis of allergic airway inflammation, as treatment of Rag1 -/-mice (which lack adaptive immune cells) with papain induced airway inflammation accompanied by eosinophilic infiltration and mucus overproduction, 64 a feature previously primarily associated with T H 2 cells. Moreover, A. alternata exposure has been reported to cause IL-33-dependent exacerbated disease in mice sensitized with an alternative allergen, 145 which, together with work on ILC2 memory, 146 suggests that antigenindependent activation of ILC2 can contribute to type 2 airway diseases. Similarly, administration of chitin or infection with the intestinal nematode Strongyloides venezuelensis was shown to trigger the production of IL-33, which led to the activation of ILC2 in the lung and caused pulmonary eosinophilia. 61 Thus, ILC2 are indirectly activated by allergens via airway epithelial cells 64, 147 (or other sources of the prototypical type 2 alarmins: IL-33, IL-25, and TSLP 49, 64, 144 ). While administration of these alarmins has the ability to induce ILC2-driven lung inflammation, IL-33 appears to be the most prominent physiological stimulus in the airways, 148, 149 whereas IL-25 is regarded to be a more prominent ILC2 activator in the gastrointestinal tract. 2 Interestingly, intranasal administration of recombinant IL-25 promotes the emergence of an IL17RB + KLRG1 hi ILC2 population in the lung. 48 Although these cells are at first ST2 -, they may convert into ST2 + ILC2 in the lung, suggesting that the tissue-specific microenvironment may strongly influence lung ILC2 regulation.
Lung ILC2 immune regulation
While ILC2 are the primary source of innate IL-5 and IL-13, the relative contribution of ILC2 compared to that of T H 2 cells in asthma has remained indefinite. In wild-type mice, ILC2 can constitute over half of the cytokine-producing immune cells after HDM or ovalbumin exposure, 144 while other studies have reported that ILC2 are redundant for development of T H 2 cells. 45 Furthermore, the findings that effector T H 2 cells are readily activated by type 2 alarmins in the absence of antigen 150 and that ILC-deficient patients experienced no increase in disease 90 provoke discussion about the importance of ILC2. Nevertheless, studies using ILC2-targeted mouse models are revealing mechanisms by which ILC2 can modulate adaptive immune function in the airways.
ILC2-deficient mice, generated by bone marrow transplantation using Rora sg/sg (Rora -/-) donors, revealed that ILC2 activity was essential for efficient T H 2 cell differentiation following airway exposure to allergen. 29, 86, 142 Several mechanisms contribute to interactions between ILC2 and CD4 + T cells; direct antigen-presentation by MHCII + ILC2 to naive CD4
+ T cells and cell-to-cell costimulation promote T H 2 cell activation and differentiation. 86, 128, 151, 152 ILC2-derived IL-13 also indirectly influences T H 2 cell differentiation by promoting lymph node homing of lung DCs. 65 Recruitment of T H 2 cells into the lung tissue was also influenced by ILC2/DC cross talk-driven CCL17 chemokine production. 153 
In addition to regulating T H 2 cells, ILC2 can also modulate ICOS
+ T reg cells in the lung through induction of ICOS-L expression. 91 Conversely, T reg cells may also suppress ILC2 to limit allergic airway inflammation. 154 Importantly, novel reagents that more selectively target ILC2 are essential to understand their precise function as immune-regulatory cells. 45, 86, 153 Nevertheless, it is clear that ILC2 are able to work in concert with adaptive immune cells, although the relevance of these interactions in human disease will need to be established.
ILC2-derived IL-13 is known to influence innate type 2 lung inflammation by promoting eosinophilia and macrophage activation. Interestingly, recent data using these mice suggest that IL-13 production by IL-33-activated ILC2 contributes to asthma pathogenesis by increasing bronchial epithelial tight junction barrier leakiness. 155 Moreover, work on neonatal mice revealed a profound increase in lung IL-33 after birth, which was associated with ILC2 proliferation and IL-13-mediated M2 macrophage polarization. 68, 156, 157 These observations suggest that, in early postnatal stages, type 2 immunity is established by IL-33-driven recruitment of inflammatory cells, in part via ILC2.
Interestingly, exposure to antigens during this neonatal period resulted in the development of allergic airway inflammation, which was minimally dependent on T H 2 cells, confirming an important role of T cell-independent activation of lung inflammation by ILC2. 68 Another recent paper highlighted the importance of ILC2-intrinsic metabolism. In this study, both mouse and human ILC2 were shown to express arginase-1, and arginine metabolism was found to control ILC2 proliferation and their production of type 2 cytokines. Ultimately, this suggests that arginine metabolism within ILC2 is able to promote type 2 allergic lung inflammation. 158 In patients, ILC2 have been detected in blood and sputum of mild and severe asthmatics, where they could promote the persistence of eosinophilic inflammation. 159 However, frequencies of circulating ILC2 in peripheral blood mononuclear cells (PBMCs) were not found to be different between allergic patients and nonallergic controls. 160 Interestingly, higher numbers of circulating ILC2 were observed in patients who presented with signs of allergic asthma compared with nonasthmatic allergic patients. 161 Moreover, the frequency of IL-13-producing ILC2 was found to be significantly higher in patients with uncontrolled asthma, whereas it was decreased dramatically when these patients had their symptoms controlled by treatment. 162 Apart from identifying ILC2 as possible predictors of asthma control, several studies have suggested these cells as possible therapeutic targets. Recent data have shown that dexamethasone exposure attenuated the production of type 2 cytokines by ILC2 and T H 2 T cells after IL-33 stimulation. 163 Others have reported that allergen-induced TSLP production makes ILC2 resistant to steroid-induced cell death through STAT5 activation, 82 and neutralization of TSLP has been shown to be effective in mild asthmatics. 84 Finally, the DP 2 receptor (CRTH2) inhibitor fevipiprant has been shown to reduce eosinophilic airway inflammation in patients with moderate-to-severe asthma despite inhaled corticosteroid treatment. 164 Taken together, these data present an important role for ILC2, not only in the initiation of allergic airway inflammation, but also in fostering a network of cellular responses and interactions with many other cells in the lung to propagate the allergic immune response.
Role of ILC2 in viral-induced infection
Besides their role in allergic lung inflammation, ILC2 also contribute to airway hyperresponsiveness (AHR) in response to respiratory viruses, like influenza, rhinovirus (RV), or respiratory syncytial virus (RSV) infection in adult and neonatal mice and humans. 165, 166 Viral infections can damage the airway epithelium and induce type 2 immune responses via the activation of epithelial cells and their subsequent production of IL-25 and IL-33. RV infection-induced epithelial IL-25 production has been shown to augment allergen-induced IL-25 production in mice and subsequently mediates RV-induced asthma exacerbations. 167 In addition, influenza studies report that activation of ILC2 during pandemic H1N1 or H3N1 influenza A viral infection results in a rapid development of AHR in an IL-33-dependent manner. 165, 168 Others have shown that enhanced ILC2 activity, in the absence of IFN-␥ , 17, 93 characterized by increased production of IL-5 and amphiregulin, exhibited decreased susceptibility to lethal infection with H1N1 influenza. 93 Studies in immature mice have shown that IFN-␥ inhibits ILC2 expansion and IL-13 production, thereby attenuating RV-induced goblet cell metaplasia and demonstrating the antagonistic function of IFN-␥ on ILC2 expansion and gene expression. 169 Moreover, deficiency in signaling through the type I interferon receptor has been shown to lead to elevated activation of ILC2. 92 This type I interferon-mediated inhibition of ILC2 proliferation and cytokine release was further suggested to be dependent on the heterotrimeric ISGF3 complex consisting of STAT1, STAT2, and IRF9. 17, 92, 94 Interestingly, influenza virus-induced inflammation in a model of chronic obstructive pulmonary disease (COPD) exacerbation initiates ILC2 plasticity. The observed conversion of ILC2 was accompanied by a significant reduction in GATA3 expression and the exposure to microenvironmental cues such as IL-12 and IL-18. 96 During RSV infection, early TSLP-dependent activation of ILC2 resulted in the production of IL-13 and the subsequent development of AHR and mucus accumulation in the absence of eosinophilia. 170 However, as in other models, IL-33 was also elevated in the lungs during RSV infection, and airway inflammatory responses were reduced in IL-33 gene KO mice, clearly showing that both TSLPR and IL-33R signaling pathways play important roles in the viral induction of type 2 immunity. 171 Interestingly, following acute influenza viral infection, accumulation of ILC2 is not only associated with immunopathology but also with tissue repair and restoration of tissue integrity. Tissue repair functions of ILC2 were IL-13 independent but relied on their production of amphiregulin. 127 Together, these studies show that, although ILC2 may have immunopathological roles during viral infection, they could seemingly induce opposite pathways restoring lung homeostasis and tissue repair after lung injury.
Skin
AD is an inflammatory skin disease characterized by epithelial barrier dysfunction and often associated with a type 2 immune response to common environmental allergens, as shown by the high levels of IL-4 and IL-13 found in skin lesions of AD patients. 172 Genes linked to susceptibility to atopic disease, such as TSLP, IL4, IL5, and IL13, are also associated with ILC2 responses. 173 Most data regarding the role of ILC2 in AD have been derived from mouse models, and these have shown that skin-resident ILC2 responses can be elicited by TSLP, IL-25, and IL-33, the vitamin D analog calcipotriol, and complexes of IL-2 with anti-IL-2 mAb. 81, 102, 174, 175 Moreover, TSLP activates a population of skin-resident ILC2 in healthy mouse and human skin, which are also enriched in dermal lesions of human AD patients, independent of IL-33R or IL-25R signaling. 81 Others have shown that mice expressing IL-33 under the keratin 14 gene promoter develop a spontaneous AD-like inflammation of the skin, associated with the infiltration of IL-5 + ILC2, 175 suggesting that, depending on the specific microenvironmental cues, ILC2 are differentially activated to produce type 2 cytokines and cooperate in AD pathogenesis. However, besides their pathological role in dermal inflammation, IL-33-activated ILC2 have been shown to harbor a protective tissue-reparative role during cutaneous wound healing. 176 Skin lesions of AD patients, but not psoriasis patients, have been shown to be enriched for ILC2 producing IL-5 and IL-13, in addition to amphiregulin (which mediates tissue repair). 177 Furthermore, the discovery that E-cadherin-KLRG1 ligation on human ILC2 shows a clear reduction in IL-5 and IL-13 production and the fact that E-cadherin is a characteristic of filaggrin insufficiency suggest that both mechanisms may cooperate in AD immunopathogenesis. 102 However, only half of the AD patients carry filaggrin mutations, and of those, 40% do not progress to allergic sensitization and the development of AD. 178, 179 Even if filaggrin deficiency and its role in barrier dysfunction on its own may not be sufficient to cause AD lesions, the absence of additional E-cadherin ligation on ILC2 may favor type 2 immune responses and the development of AD skin lesions. Moreover, ILC2 have been demonstrated to be the predominant IL-13-producing cell population in the skin, and elevated IL-13 levels in the skin predispose mice for the development of skin lesions. 174, 175 Therefore, there has been great interest in blocking IL-13 as a therapeutic intervention strategy. The blocking of IL-13 activity in humans through dupilumab has been shown to alleviate the symptoms of atopic disease. 59 Together, data from GWAS of patients and data collected from human studies and mouse models suggest that skin-resident ILC2 play a prominent role in the pathogenesis of AD, although additional work is awaited to elucidate the exact role of ILC2 in the skin.
The role of ILC2 in other anatomical sites
It is becoming increasingly clear that ILC2 are not restricted to mucosal barrier sites, but are present in numerous other tissues. In the liver, ILC2 have been associated with IL-33-induced liver fibrosis. It has been demonstrated that IL-33 released by stressed hepatocytes activates ILC2, which trigger the IL-13-dependent profibrogenic activation of hepatic stellate cells. 180, 181 IL-33 is further elevated in models of viral hepatitis; however, in this model, ILC2 have been suggested to limit liver injury.
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ILC2 have also been found in the brain meningeal space, where they respond to spinal cord injury by the production of type 2 cytokines. 183 In addition, brain-resident ILC2 were found to polarize the immune response to cerebral malaria. 184 ILC2 in the nervous system may also play a role in multiple sclerosis. ILC2 were found to accumulate in the brain and draining lymph nodes of mice resistant to experimental autoimmune encephalitis. 185 Although far from exhaustive, the implications of ILC2 in the diseases described above and their discovery in numerous mucosal and nonbarrier tissues indicate the importance of considering these cells in an increasing number of organs and diseases.
Conclusion and future directions
Since their discovery as an innate source of type 2 cytokines in the gut, ILC2 have been identified in an expanding number of other anatomical locations. Their tissue residency reflects their sentinel function and role in tissue homeostasis. It is becoming increasingly evident that ILC2 are intricately involved in regulating both immune and nonimmune cell types. Conversely, ILC2 function is tightly modulated by diverse upstream factors. As such, it is likely that ILC2 are an important tissue-specific nexus between immune and nonhematopoietic cells in type 2 immunity. Importantly, findings of mouse ILC2 biology will need to be translated into humans to resolve their importance in disease.
Nevertheless, intriguing findings in murine models show that ILC2 are essential in the initiation and propagation of allergic type 2 immune responses from birth to adulthood. The identification of ILC2 and the further insight into their function in inflammation and tissue repair have highlighted the important role of this type of ILC in triggering immunity. Recent mouse and human data together allow us to become increasingly aware of the fact that ILC2 responses are greatly influenced by their interactions with microbiota, nutrients, metabolites, neurons, and stromal cells. However, specific microenvironmental factors mediating the plasticity of ILC2 have not been identified, and the molecular mechanisms underlying ILC2 interaction with their environment remain poorly understood, although the use of transcriptomic data sets can further enable investigations into this issue. 112 It is expected that future studies will provide more detailed answers to the remaining outstanding questions and lead to the development of novel and effective therapy for ILC2-driven diseases.
